Julian Adams, PhD, from Infinity Pharmaceuticals, discusses PI3K inhibitors and chemotherapies for the treatment of hematologic malignancies.
Julian Adams, PhD, President, Research and Development, Infinity Pharmaceuticals, discusses PI3K inhibitors and chemotherapies for the treatment of hematologic malignancies.
Traditionally, patients are treated with chemotherapy and anti-CD20 therapies. Eventually, Adams says, patients relapse and are no longer responsive. A further challenge arises in that many of these patients are elderly and cannot tolerate aggressive chemotherapies.
Adams says that targeted therapies such as PI3K-delta and PI3K-gamma inhibitors will obviate the need for harsh therapies. With these therapies, physicians will be able to rescue patients from their chronic and aggressive diseases.